IHL-675A: Advancing Towards Innovative Arthritis Solutions, with Mark Bleackley, PhD

Mark Bleackley, PhD, discusses the upcoming phase 2 trial of IHL-675A designed to explore arthritis treatment through dual-drug comparison, promising global expansion, and its impact on patients’ pain relief.

Related Keywords

Australia ,Mark Bleackley ,Incannex Healthcare ,Chief Scientific Officer ,Incannex Healthcare Limited ,Routine Assessment ,Patient Index Data ,